BI
XFOR icon

BVF Inc’s X4 Pharmaceuticals XFOR Stock Holding History

BVF Inc’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.23M Hold
2,233,742
– – 0.29% 33
2025
Q4 		$8.93M Hold
2,233,742
– – 0.3% 33
2025
Q3 		$7.64M Buy
+2,233,742
New +$5.76M 0.31% 36
2023
Q1 		– Sell
-44,922
Closed -$1.34M – 79
2022
Q4 		$1.34M Buy
44,922
+16,659
+59% +$789K 0.06% 71
2022
Q3 		$1.45M Hold
28,263
– – 0.06% 70
2022
Q2 		$818K Hold
28,263
– – 0.04% 77
2022
Q1 		$1.48M Hold
28,263
– – 0.06% 77
2021
Q4 		$1.94M Hold
28,263
– – 0.07% 79
2021
Q3 		$4.49M Hold
28,263
– – 0.18% 70
2021
Q2 		$5.51M Sell
28,263
-8,123
-22% -$2.04M 0.21% 59
2021
Q1 		$9.4M Buy
36,386
+9,956
+38% +$2.62M 0.35% 51
2020
Q4 		$5.1M Hold
26,430
– – 0.2% 56
2020
Q3 		$5.37M Sell
26,430
-7,266
-22% -$1.74M 0.29% 52
2020
Q2 		$9.42M Sell
33,696
-5,362
-14% -$1.47M 0.58% 41
2020
Q1 		$11.7M Buy
39,058
+992
+3% +$281K 1.09% 26
2019
Q4 		$12.2M Buy
38,066
+18,284
+92% +$6.56M 0.93% 26
2019
Q3 		$7.54M Buy
19,782
+432
+2% +$171K 0.79% 36
2019
Q2 		$8.71M Buy
+19,350
New +$9.84M 0.95% 33

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BVF Inc's XFOR Position: Q1 2026 in Review

BVF Inc held its X4 Pharmaceuticals (XFOR) position steady in Q1 2026 at 2,233,742 shares worth $9.23M. The position accounts for 0.29% of the portfolio, ranked #33.

BVF Inc first reported a position in XFOR in Q2 2019 and has held it in 18 quarters since. The position peaked at $12.2M in Q4 2019. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • BVF Inc held 2,233,742 shares of X4 Pharmaceuticals worth $9.23M as of Q1 2026.
  • BVF Inc left its X4 Pharmaceuticals share count unchanged in Q1 2026.
  • X4 Pharmaceuticals made up 0.29% of BVF Inc's portfolio in Q1 2026, its #33 holding.
  • BVF Inc first reported a position in X4 Pharmaceuticals in Q2 2019 and has held it in 18 quarters since.
  • BVF Inc's X4 Pharmaceuticals position peaked at $12.2M in Q4 2019.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on BVF Inc's 13F filing for Q1 2026, filed 15 May 2026.